Search

Your search keyword '"Willekens, Christophe"' showing total 281 results

Search Constraints

Start Over You searched for: Author "Willekens, Christophe" Remove constraint Author: "Willekens, Christophe"
281 results on '"Willekens, Christophe"'

Search Results

51. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening.

52. The Impact of Risk-adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplant

53. Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study

54. Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML

55. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

56. Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

57. Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis

58. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

60. Allogeneic Hematopoietic Stem Cell Transplant in Elderly Patients Using Reduce Intensity Conditioning Regimen: A Single Centre Experience

61. Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines

62. Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma

63. Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

64. Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

65. Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

66. Invasive cutaneous infection due to Scopulariopsis brevicaulis unsuccessfully treated with high-dose micafungin in a neutropenic patient

67. 1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis

68. Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

69. Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation

71. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type

72. Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.

73. The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

74. Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

75. An Unusual Case of Constitutional Mismatch Repair Deficiency Syndrome With Anaplastic Ganglioglioma, Colonic Adenocarcinoma, Osteosarcoma, Acute Myeloid Leukemia, and Signs of Neurofibromatosis Type 1

76. AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

77. Concurrent Radiation and ESHAP Regimen in Localized Extranodal NK/T-Cell Lymphoma Nasal Type, Phase II French Study

78. A Simple Scoring System for Identifying Relapsed/Refractory Lymphoma Patients Prematurely Withdrawn from Phase I Trials: The Gustave Roussy Experience

81. Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.

82. Results of treatment with 5-azacytidine in patients treated for myelodysplastic syndrome or secondary acute myeloid leukemia associated with a concomitant active cancer.

83. Minimal residual disease monitoring int(8;21) acute myeloid leukemia based onRUNX1-RUNX1T1fusion quantification on genomic DNA

84. Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML)

85. AML At First Relapse: A Real Life Picture

88. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.

89. Enasidenib in mutant IDH2relapsed or refractory acute myeloid leukemia

93. Prognostic Value of PINI in Elderly Patients with Multiple Myeloma (MM).

94. Bortezomib and Waldenstrom's macroglobulinemia

97. Identification of a New Mutation on the β-Globin Gene: Codons 8/9 (+AGAA); GAG.AAG.TCT(Glu-Lys-Ser)>GAG. AA AGAAG, in a Patient From the North of France with a Phenotype of β-Thalassemia Minor.

100. ATG2B/Gskipin De NovoAcute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

Catalog

Books, media, physical & digital resources